Crucell NV is currently developing the only adjuvanted flu vaccine against the influenza virus licensed for all age groups but Crucell stock hasn’t match analyst expectations showing a 20% increase since April 2009.

With their innovative and top selling product, the PFL N95 mask, currently meets both WHO and CDC protection levels in order to project individuals from the spreads of the influenza virus from individuals suffering the swine flu symptoms. Alpha Pro Tech share price has increased 250% since April 2009. More to come?

Sinovac Biotech is one of the top pharmaceutical companies that has a swine flu vaccine being tested with possible production starting in September. Since the first swine flu symptoms were reported in Mexico in April 2009, Sinovac Biotech stock has jumped over 200% exceeding analyst expectations. How much higher can Sinovac Biotech share price go?

Roche share price hasn’t exceeded the 20% return since the first swine flu symptoms were reported in Mexico in April 2009, a clear indication that Tamiflu is not the solution to the swine flu pandemic. Relenza, produced by GlaxoSmithKline, is also reporting the same ineffective results primarily over children under 12.

Inovio has two flu vaccines at late stages of the product pipeline. Their VGX-3400 and its universal influenza vaccine have also shown positive results during development and trial stages. However, other companies like AVI BioPharma (AVII) and Antigenics (AGEN) might win the race for the first swine flu vaccine

The competitive advantage from top pharmaceutical companies has also been mimicked by the top biotech companies as the industry emerges as a leading player in the swine flu research. The swine flu pandemic is now recognized as one of the most profitable opportunities ever encountered by healthcare sector.

Healthcare is a multi billion dollar a year industry and with aging baby-boomer investors helping to fuel production, this industry will continue. Global health problems like Cancer, HIV, Diabetes, and the swine flu pandemic mean there is no shortage of research and development to be done. And for investors, the discovery of the first swine flu vaccine will mean big profits.

The right stock pick will clearly be based on a long term approach rather than on a get-rich-quick-scheme. A swine flu vaccine developed by any biotech companies will send their stocks soaring; you just have to look at their fundamentals, leave the gambling spirit on the side and focus on a long term investment strategy.